| Landscape of somatic mutations in 560 breast cancer whole-genome sequences S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ... Nature 534 (7605), 47-54, 2016 | 2177 | 2016 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1686* | 2020 |
| MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy GW Sledge Jr, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... Journal of clinical oncology 35 (25), 2875-2884, 2017 | 1480 | 2017 |
| Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer S Johnston, J Pippen Jr, X Pivot, M Lichinitser, S Sadeghi, V Dieras, ... Journal of Clinical Oncology 27 (33), 5538-5546, 2009 | 1238 | 2009 |
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1075 | 2010 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 952 | 2018 |
| The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a … GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, ... JAMA oncology 6 (1), 116-124, 2020 | 794 | 2020 |
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment ES Thomas, HL Gomez, RK Li, HC Chung, LE Fein, VF Chan, J Jassem, ... Journal of Clinical Oncology 25 (33), 5210-5217, 2007 | 659 | 2007 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 652 | 2020 |
| Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ... The lancet oncology 14 (10), 933-942, 2013 | 508 | 2013 |
| Malnutrition is an independent factor associated with nosocomial infections SM Schneider, P Veyres, X Pivot, AM Soummer, P Jambou, J Filippi, ... British journal of nutrition 92 (1), 105-111, 2004 | 477 | 2004 |
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The lancet oncology 14 (8), 741-748, 2013 | 453 | 2013 |
| Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine EA Perez, G Lerzo, X Pivot, E Thomas, L Vahdat, L Bosserman, P Viens, ... Journal of Clinical Oncology 25 (23), 3407-3414, 2007 | 447 | 2007 |
| Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2–positive, advanced breast cancer: primary results … EA Perez, C Barrios, W Eiermann, M Toi, YH Im, P Conte, M Martin, ... Journal of Clinical Oncology 35 (2), 141, 2017 | 428 | 2017 |
| Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent … D Miles, A Chan, G Romieu, LY Dirix, J Cortes, X Pivot, P Tomczak, ... Journal of clinical oncology 26 (15_suppl), LBA1011-LBA1011, 2008 | 319 | 2008 |
| Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal … J Cortés, P Fumoleau, GV Bianchi, TM Petrella, K Gelmon, X Pivot, ... J Clin Oncol 30 (14), 1594-1600, 2012 | 303 | 2012 |
| AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic … L Gianni, GH Romieu, M Lichinitser, SV Serrano, M Mansutti, X Pivot, ... J Clin Oncol 31 (14), 1719-1725, 2013 | 291 | 2013 |
| CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth … X Pivot, A Manikhas, B Żurawski, E Chmielowska, B Karaszewska, ... Journal of Clinical Oncology 33 (14), 1564-1573, 2015 | 268 | 2015 |
| Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up L Zelek, A Llombart-Cussac, P Terrier, X Pivot, JM Guinebretiere, ... Journal of Clinical Oncology 21 (13), 2583-2588, 2003 | 265 | 2003 |
| Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study X Pivot, J Gligorov, V Müller, P Barrett-Lee, S Verma, A Knoop, ... The lancet oncology 14 (10), 962-970, 2013 | 251 | 2013 |
